Match!
Áron Gellert
Hazard ratioChemotherapyBevacizumabAdenocarcinomaKRAS
1Publications
0Citations
What is this?
Publications 1
Newest
#1Áron GhimessyH-Index: 2
Last. Balazs DomeH-Index: 28
view all 18 authors...
Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angiogenesis has been well established, its prognostic and predictive role in the above setting remains unclear. The association between KRAS exon 2 mutational status and clinicopathological variables inc...
Source
1